Antifungal therapy in children: An update

European Journal of Pediatrics

Volumn 172, Issue 4, 2013, Pages 437-446

  Cecinati, Valerio ^a   Guastadisegni, Chiara ^b   Russo, Fabio Giovanni ^c   Brescia, Letizia Pomponia ^d  

^a SPIRITO SANTO HOSPITAL   (Italy)

^b POLICLINICO   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITY OF BARI   (Italy)

Author keywords

Antimycotic drugs; Children; Fungal infections

Indexed keywords

ABELCED; ALBACONAZOLE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CLOTRIMAZOLE; E 1224; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ISAVUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; POSACONAZOLE; RAVUCONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; CHILD CARE; CHILDHOOD DISEASE; CHROMOMYCOSIS; COCCIDIOIDOMYCOSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEBRILE NEUTROPENIA; FUSARIOSIS; HUMAN; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LUNG ASPERGILLOSIS; MUCORMYCOSIS; MYCOSIS; MYELOID LEUKEMIA; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; SYSTEMATIC REVIEW;

ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; MYCOSES;

EID: 84876694428     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/s00431-012-1758-9     Document Type: Review

References (85)

1. Andes D (2003) In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother 43 (S38):161-189
2. Andes D (2004) Clinical utility of antifungal pharmacokinetics and pharmacodynamics. Curr Opin Infect Dis 17:533-540
3. Antachopoulos C, Walsh TJ (2005) New agents for invasive mycoses in children. Curr Opin Pediatr 17:78-87
4. Ben-Ami R, Lewis RE, Kontoyiannis DP (2008) Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis 47:226-235
5. Benjamin DK Jr, Driscoll T, Seibel NL, Gonzalez CE, Roden MM, Kilaru R, Clark K, Dowell JA, Schranz J, Walsh TJ (2006) Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 50:632-638
6. Brammer KW, Coates PE (1994) Pharmacokinetics of fluconazole in pediatric patients. Eur J Clin Microbiol Infect Dis 13(4):325-329
7. Cancidas (caspofungin) [package insert] (2009) Whitehouse Station (NJ): Merck & Co. Inc
8. Carter NJ, Keating GM (2009) Micafungin: a review of its use in the prophylaxis and treatment of invasive candida infections in pediatric patients. Paediatr Drugs 11:271-291
9. Cesaro S, Milano GM, Aversa F (2011) Retrospective survey on the off-label use of posaconazole in pediatric hematology patients. Eur J Clin Microbiol Infect Dis 30:595-596
10. Chandrasekar PH, Sobel JD (2006) Micafungin: a new echinocandin. Clin Infect Dis 42:1171-1178
11. Charlier C, Hart E, Lefort A, Ribaud P, Dromer F, Denning DW, Lortholary O (2006) Fluconazole for the management of invasive candidiasis:where do we stand after 15 years? JAntimicrob Chemother 57:384-410
12. Chen SC, Slavin MA, Sorrell TC (2011) Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 71:11-41
13. Cornely OA, Lasso M, Betts R, Klimko N, Vazquez J, Dobb G, Velez J, Williams-Diaz A, Lipka J, Taylor A, Sable C, Kartsonis N (2007) Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 60:363-369
14. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary O, Rieger C, Boehme A, Aoun M, Horst HA, Thiebaut A, Ruhnke M, Reichert D, Vianelli N, Krause SW, Olavarria E, Herbrecht R, AmBiLoad Trial Study Group (2007) Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a highloading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44:1289-1297
15. Craiglow B, Hinds G, Antaya R, Girardi M (2009) Primary cutaneous aspergillosis in an immunocompetent patient: successful treatment with oral voriconazole. Pediatr Dermatol 26:493-495
16. De Beule K, Van Gestel J (2001) Pharmacology of itraconazole. Drugs 61:27-37
17. Denning DW, Marr KA, Lau WM, Ratanatharathorn V, Becker C, Ullmann AJ, Seibel NL, Flynn PM, van Burik JA, Buell DN, Patterson TF (2006) Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 53:337-349
18. Frampton JE, Scott LJ (2008) Posaconazole: a review of its usein the prophylaxis of invasive fungal infections. Drugs 68:993- 1016
19. Garnock-Jones KP, Keam SJ (2009) Caspofungin in pediatric patients with fungal infectons. Paediatr Drugs 11:259-269
20. Groll AH, Attarbaschi A, Schuster FR, Herzog N, Grigull L, Dworzak MN, Beutel K, Laws HJ, Lehrnbecher (2006) Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey. J Antimicrob Chemother 57:527-535
21. Groll AH, Piscitelli SC,Walsh TJ (1998) Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 44:343-500
22. Groll AH, Tragiannidis A (2010) Update on antifungal agents for paediatric patients. Clin Microbiol Infect 9:1343-1353
23. Groll AH, Walsh TJ (2001) Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs 10:1545-1558
24. Groll AH, Walsh TJ (2005) Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther 3:467-487
25. Gupta AK, Cooper EA, Ginter G (2003) Efficacy and safety of itraconazole use in children. Dermatol Clin 21:521-535
26. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B, Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408-415
27. Hilliard T, Edwards S, Buchdahl R, Francis J, Rosenthal M, Balfour-Lynn I, Bush A, Davies J (2005) Voriconazole therapy in children with cystic fibrosis. J Cyst Fibros 4:215-220
28. Homans JD, Spencer L (2010) Itraconazole treatment of nonmeningeal coccidioidomycosis in children: two case reports and review of the literature. Pediatr Infect Dis J 29(1):65-67
29. Hope WW, Seibel NL, Schwartz CL, Arrieta A, Flynn P, Shad A, Albano E, Keirns JJ, Buell DN, Gumbo T, Drusano GL, Walsh TJ (2007) Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 51:3714-3719
30. Ikeda F, Tanaka S, Ohki H, Matsumoto S, Maki K, Katashima M, Barrett D, Aoki Y (2007) Role of micafungin in the antifungal armamentarium. Curr Med Chem 14:1263-1275
31. Karlsson MO, Lutsar I, Milligan PA (2009) Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 53:935
32. Kaya Z, Gursel T, Kocak U, Aral YZ, Kalkanci A, Albayrak M (2009) Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis. Pediatr Blood Cancer 52:470-475
33. Keating GM (2005) Posaconazole. Drugs 65:1553-1567
34. Kontoyiannis DP, Ratanatharathorn V, Young JA, Raymond J, Laverdière M, Denning DW, Patterson TF, Facklam D, Kovanda L, Arnold L, Lau W, Buell D, Marr KA (2009) Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis 11:89-93
35. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA, Micafungin Invasive Candidiasis Working Group (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369:1519-1527
36. Lehrnbecher T, Attarbaschi A, Duerken M, Garbino J, Gruhn B, Kontny U, Lüer S, Phillips R, Scholz J, Wagner HJ, Wiesel T, Groll AH (2010) Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis 29:1043-1045
37. Maertens JA, Madero L, Reilly AF, Lehrnbecher T, Groll AH, Jafri HS, Green M, Nania JJ, Bourque MR, Wise BA, Strohmaier KM, Taylor AF, Kartsonis NA, Chow JW, Arndt CA, DePauw BE, Walsh TJ, Caspofungin Pediatric Study Group (2010) A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 29:415-420
38. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ, Caspofungin Salvage Aspergillosis Study Group (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39:1563-1571
39. Marr KA, Leisenring W, Crippa F, Slattery JT, Corey L, Boeckh M, McDonald GB (2004) Cyclophosfamide metabolism is affected by azole antifungals. Blood 103:1557-1559
40. Moen MD, Lyseng-Williamson KA, Scott LJ (2009) Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 69:361-392
41. Mondal RK, Singhi SC, Chakrabarti A (2004) Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit: a preliminary study. Pediatr Crit Care Med 5:561-565
42. Morgenstern GR, Prentice AG, Prentice HG, Ropner JE, Schey SA, Warnock DW (1999) A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. Br J Haematol 105:901-911
43. Mouas H, Lutsar I, Dupont B, Fain O, Herbrecht R, Lescure FX, Lortholary O, Voriconazole/Bone Invasive Aspergillosis Study Group (2005) Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis 40:1141-1147
44. Natarajan G, Lulic-Botica M, Rongkavilit C, Pappas A, Bedard M (2005) Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 25:770-777
45. Neely M, Jafri HS, Seibel N, Knapp K, Adamson PC, Bradshaw SK, Strohmaier KM, Sun P, Bi S, Dockendorf MF, Stone JA, Kartsonis NA (2009) Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother 53:1450-1456
46. Odio CM, Araya R, Pinto LE, Castro CE, Vasquez S, Alfaro B, Sàenz A, Herrera ML, Walsh TJ (2004) Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis 23:1093- 1097
47. Pannaraj PS, Walsh TJ, Baker CJ (2005) Advances in antifungal therapy. Pediatr Infect Dis J 24:921-922
48. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE,Walsh TJ, Edwards JE, Infectious Diseases Society of America (2004) Guidelines for treatment of candidiasis. Clin Infect Dis 38:161-189
49. Pasqualotto AC, Thiele KO, Goldani LZ (2010) Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole. Curr Opin Investig Drugs 11:165-174
50. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis 50:291-322
51. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ (2008) In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 46:150-156
52. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ (2008) In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol 46:2568-2572
53. Queiroz-Telles F, Berezin E, Leverger G, Freire A, van der Vyver A, Chotpitayasunondh T, Konja J, Diekmann-Berndt H, Koblinger S, Groll AH, Arrieta A, Micafungin Invasive Candidiasis Study Group (2008) Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 27:820-826
54. Raymond J, Laverdière M, Denning DW, Patterson TF, Facklam D, Kovanda L, Arnold L, Lau W, Buell D, Marr KA (2007) Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 51:812- 818
55. Rogers TR, Frost S (2009) Newer antifungal agents for invasive fungal infections in patients with haematological malignancy. Br J Haematol 144:629-641
56. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel JD, Dismukes WE (2000) Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 30:710-718
57. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM (2006) In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 50:2009-2015
58. Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, Schuler U, Lutsar I, Troke P, Thiel E (2005) Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 106:2641-2645
59. Scott LJ, Simpson D (2007) Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 67:269-298
60. Segal BH, Barnhart LA, Anderson VL, Walsh TJ, Malech HL, Holland SM (2005) Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis 40:1684-1688
61. Seibel NL, Schwartz C, Arrieta A et al (2005) Safety, tolerability and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 49:3317-3324
62. Steinbach WJ (2005) Antifungal agents in children. Pediatr Clin North Am 52:895-915
63. Steinbach WJ (2010) Invasive aspergillosis in pediatric patients. Curr Med Res Opin 26:1779-1787
64. Stone JA, Migoya EM, Hickey L, Winchell GA, Deutsch PJ, Ghosh K, Freeman A, Bi S, Desai R, Dilzer SC, Lasseter KC, Kraft WK, Greenberg H, Waldman SA (2004) Potential for interaction between caspofungin and nelfinavir or rifampicin. Antimicrob Agents Chemother 48:4306-4314
65. Sucher AJ, Chahine EB, Balcer HE (2009) Echinocandins: the newest class of antifungals. Ann Pharmacother 43:1647-1657
66. Tarani L, Costantino F, Notheis G, Wintergerst U, Venditti M, Di Biasi C, Friederici D, Pasquino AM (2009) Long-term posaconazole treatment and follow-up of rhino-orbital-cerebral mucormycosis in a diabetic girl. Pediatr Diabetes 10:289-293
67. Thompson GR 3rd, Cadena J, Patterson TF (2009) Overview of antifungal agents. Clin Chest Med 30:203-215
68. Ting JY, Chan SY, Lung DC, Ho AC, Chiang AK, Ha SY, Tsoi NN, Chan GC (2010) Intra-abdominal Rhizopus microsporus infection successfully treated by combined aggressive surgical, antifungal, and iron chelating therapy. J Pediatr Hematol Oncol 32:238-240
69. Troke P, Aguirrebengoa K, Arteaga C, Ellis D, Heath CH, Lutsar I, Rovira M, Nguyen Q, Slavin M, Chen SC, Global Scedosporium Study Group (2008) Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 52:1743-1750
70. van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, Lee JM, Walsh TJ, National Institute of Allergy and Infectious Diseases Mycoses Study Group (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39:1407-1416
71. van de Sande WW, van Vianen W, ten Kate MT, Vissers J, Laurijsens J, Tavakol M, Rijnders BJ, Mathot RA, Bakker- Woudenberg IA (2008) Caspofungin prolongs survival of transiently neutropenic rats with advanced-stage invasive pulmonary aspergillosis. Antimicrob Agents Chemother 52:1345-1350
72. van Vianen W, de Marie S, ten Kate MT, Mathot RA, Bakker- Woudenberg IA (2006) Caspofungin :antifungl activity in vitro, pharmacokinetics and effects on fungal load and animal survival in neutopenic rats with invasive pulmonary apergillosis. J Antimicrob Chemother 57:732-740
73. VandenBussche HL, Van Loo DA (2010) A clinical review of echinocandins in pediatric patients. Ann Pharmacother 44:166-177
74. Walsh TJ, Adamson PC, Seibel NL, Flynn PM, Neely MN, Schwartz C, Shad A, Kaplan SL, Roden MM, Stone JA, Miller A, Bradshaw SK, Li SX, Sable CA, Kartsonis NA (2005) Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 49:4536-4545
75. Walsh TJ, Anaissie EJ, Denning DW (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327-360
76. Walsh TJ, Dixon DM (1996) Spectrum of mycoses source medical microbiology, 4th edn. University of Texas Medical Branch at Galveston, Galveston, Chapter 75
77. Walsh TJ, Driscoll T, Milligan PA, Wood ND, Schlamm H, Groll AH, Jafri H, Arrieta AC, Klein NJ, Lutsar I (2010) Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother 54:4116-4123
78. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, Milligan P, Wood N (2004) Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 48:2166-2172
79. Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, Hodges M, Groll AH, Perfect JR (2002) Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 21:240-248
80. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdière M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J, National Institute of Allergy and Infectious Diseases Mycoses Study Group (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225-234
81. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391-1402
82. Walsh TJ, Viviani MA, Arathoon E, Chiou C, Ghannoum M, Groll AH, Odds FC (2000) New targets and delivery systems for antifungal therapy. Med Mycol 38:335-347
83. Wildfeuer A, Laufen H, Schmalreck AF, Yeates RA, Zimmermann T (1997) Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility. Mycoses 40(7-8):259-265, Nov 84. Zaoutis T (2010) Candidemia in children. Curr Med Res Opin 26:1761-1768
84. Zaoutis TE, Benjamin DK, Steinbach WJ (2005) Antifungal treatment in pediatric patients. Drug Resist Updat 8:235-245
85. Zaoutis TE, Jafri HS, Huang LM, Locatelli F, Barzilai A, Ebell W, Steinbach WJ, Bradley J, Lieberman JM, Hsiao CC, Seibel N, Laws HJ, Gamba M, Petrecz M, Taylor AF, Strohmaier KM, Chow JW, Kartsonis NA, Ngai AL (2009) A prospective, multicenter study of caspofungin for the treatment of documented candida or aspergillus infections in pediatric patients. Pediatrics 123:877-884